Glucagon-like peptide-1 (GLP-1) receptor agonists are not associated with an increased risk for suicidality compared with dipeptidyl peptidase-4 (DPP-4) inhibitors or sodium-glucose cotransporter-2 ...

With respect to risks, GLP-1RA use was significantly associated with an increased risk of gastrointestinal disorders, hypotension, syncope, arthritic disorders, drug-induced pancreatitis, and other ...

People who take weight-loss drugs based on GLP-1 receptor agonists seem to have ... including sulfonylureas, DPP4 inhibitors and SGLT2 inhibitors. Compared to usual care, GLP-1RA use was linked ...

After adjustment for confounding variables, researchers found no increased suicide risk for GLP-1 receptor agonists versus DPP-4 inhibitors or SGLT-2 inhibitors. HealthDay News — Glucagon-like peptide ...

After accounting for confounding factors, the perceived increased incidence of suicidality with GLP-1 receptor agonist vs DPP-4 inhibitor use was decreased to a null value. (HealthDay News ...

Rybelsus (semaglutide) is the first GLP-1 agonist drug that can be dosed orally ... (crisaborole), a topical phosphodiesterase 4 (PDE-4) inhibitor for atopic dermatitis already sold as Eucrisa ...

SGLT2 inhibitors and GLP-1RAs yielded lower risks for COPD exacerbation than DPP-4 inhibitors among patients with type 2 diabetes.

The risk for moderate or severe COPD exacerbation was lower among those treated with SGLT-2is and with GLP-1 RAs versus DPP-4is.